BIONOS BIOTECH SL

Their core work

Bionos Biotech is a Valencia-based biotech SME specializing in microalgae-derived products for cosmetics and nutrition, as well as biological tools for disease diagnostics and vector control. They contribute expertise in multi-omics approaches (genomics, transcriptomics, proteomics, enzymomics) to EU research consortia. Their work spans from developing natural UV sunscreens and nutraceuticals from algae to supporting research on insecticide development targeting malaria vectors.

What they specialise in

How they've shifted over time

Bionos entered H2020 in 2015 through health diagnostics (PHOCNOSIS, cardiovascular point-of-care devices), then shifted toward bio-based product development from microalgae with AlgaeCeuticals (2018–2023). Their most recent project, CypTox (2021–2025), moves into vector-borne disease and insecticide development, suggesting a broadening from product-oriented biotech toward applied life sciences with a public health dimension.

Bionos is moving from pure product development toward applied biological research with public health relevance, particularly in tropical disease vectors and natural bioactive compounds.

How they like to work

Bionos has participated exclusively as a consortium partner across all three projects, never as coordinator, indicating they serve as a specialist contributor rather than a project leader. With 34 unique partners across 14 countries from just 3 projects, they join large, internationally diverse consortia — typical of MSCA-RISE mobility networks. This suggests they are open to broad collaboration and comfortable working across cultures and disciplines.

Despite only three projects, Bionos has built a wide network of 34 partners across 14 countries, reflecting the large consortium sizes typical of MSCA-RISE actions. Their reach is genuinely pan-European and likely extends to non-EU partners given the RISE mobility format.

What sets them apart

Bionos sits at an unusual intersection of microalgae biotechnology, multi-omics analytical capabilities, and applied health research — a combination rarely found in a single SME. Their capacity to bridge natural product development (cosmeceuticals, nutraceuticals) with disease-related research (diagnostics, vector control) makes them a versatile partner. For consortium builders, they offer private-sector biotech expertise with hands-on lab capability, which strengthens proposals needing industry involvement.

Highlights from their portfolio

• AlgaeCeuticals
  Core to Bionos's identity — microalgae-based product development combining multi-omics with commercial cosmeceutical and nutraceutical applications.
• PHOCNOSIS
  Largest single EC contribution (EUR 227,000) and demonstrates capability in advanced diagnostics hardware, a departure from their biotech core.
• CypTox
  Most recent project signaling a new direction into insecticide research and malaria vector control, expanding their scope toward global health challenges.